Publications

BibTex format

@article{Adcock:2021:10.3389/fonc.2021.715677,
author = {Adcock, I and Dezfuli, NK and Alipoor, SD and Roofchayee, ND and Seyfi, S and Salimi, B and Mortaz, E},
doi = {10.3389/fonc.2021.715677},
journal = {Frontiers in Oncology},
pages = {1--12},
title = {Evaluation expression of miR-146a and miR-155 in non-small cell lung cancer patients},
url = {http://dx.doi.org/10.3389/fonc.2021.715677},
volume = {11},
year = {2021}
}

Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Background: Non−small-cell lung cancer (NSCLC) is the major type of lung cancer. MicroRNAs (miRNAs) are novel markers and targets in cancer therapy and can act as both tumor suppressors and oncogenes and affect immune function. The aim of this study was to investigate the expression of miR146a and miR155 in linked to blood immune cell phenotypes and serum cytokines in NSCLC patients.Methods: Thirty-three NSCLC patients and 30 healthy subjects were enrolled in this study. The allele frequencies of potential DNA polymorphisms were studied using polymerase chain reaction (PCR)–restriction fragment length polymorphism (PCR-RFLP) analysis in peripheral blood samples. Quantitative reverse transcription PCR (qRT-PCR) was used to measure the expression of miR-146a and miR-155 in peripheral blood mononuclear cells (PBMCs). Serum cytokine (IL-1β, IL-6, TNF-α, TGF-β, IL-4, IFN-γ) levels were determined by ELISA. The frequency of circulating CD3+CTLA-4+ and CD4+CD25+FOXP3+ (T regulatory cells/Treg) expression was measured by flow cytometry.Results: miR-146a was significantly downregulated in PBMC of NSCLC patients (P ≤ 0.001). Moreover, IL-6 and TGF-β levels were elevated in NSCLC patients (P ≤ 0.001, P ≤ 0.018, respectively). CD3+ CTLA-4+ and Treg cells frequencies were higher in patients than in control subjects (P ≤ 0.0001, P ≤ 0.0001, respectively). There was a positive correlation between miR-155 and IL-1β levels (r=0.567, p ≤ 0.001) and a negative correlation between miR-146a and TGF-β levels (r=-0.376, P ≤ 0.031) in NSCLC patients. No significant differences were found in the relative expression of miR-146a and miR-155, cytokine levels or immune cell numbers according to miR-146a and miR-155 (GG/GC/CC, TT/AT/AA) genotypes. However, there was a positive correlation between miR-146a and IL-1β levels (r=0.74, P ≤ 0.009) in GG subjects and a positive correlation between miR-146a expression and CD3+
AU  - Adcock,I
AU  - Dezfuli,NK
AU  - Alipoor,SD
AU  - Roofchayee,ND
AU  - Seyfi,S
AU  - Salimi,B
AU  - Mortaz,E
DO  - 10.3389/fonc.2021.715677
EP  - 12
PY  - 2021///
SN  - 2234-943X
SP  - 1
TI  - Evaluation expression of miR-146a and miR-155 in non-small cell lung cancer patients
T2  - Frontiers in Oncology
UR  - http://dx.doi.org/10.3389/fonc.2021.715677
UR  - https://www.frontiersin.org/articles/10.3389/fonc.2021.715677/full
UR  - http://hdl.handle.net/10044/1/92591
VL  - 11
ER  -

Download

ProfessorIanAdcock

Contact

Location

Summary

Citation

BibTex format

RIS format (EndNote, RefMan)